Patents by Inventor Joshua C. Doloff

Joshua C. Doloff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified alginates for anti-fibrotic materials and applications
    Patent number: 11266606
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: March 8, 2022
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS
    Publication number: 20220031913
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: July 15, 2021
    Publication date: February 3, 2022
    Inventors: Arturo Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Modified alginates for anti-fibrotic materials and applications
    Patent number: 11090413
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 17, 2021
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATON
    Inventors: Arturo Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Modified alginates for anti-fibrotic materials and applications
    Patent number: 10898443
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: January 26, 2021
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Compositions of crystallized hydrophobic compounds and methods of making and using same
    Patent number: 10851069
    Abstract: The present invention provides, in certain embodiments, compositions comprising a uniform population of free, single crystals of a hydrophobic compound. Methods of administering, and processes for preparing, compositions comprising a uniform population of free, single crystals of a hydrophobic compound are also provided.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: December 1, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Shady Farah, Joshua C. Doloff, Robert S. Langer, Daniel G. Anderson
  • Modified alginates for anti-fibrotic materials and applications
    Patent number: 10729818
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 4, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Modified alginates for anti-fibrotic materials and applications
    Patent number: 10709818
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: July 14, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS
    Publication number: 20200016085
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 16, 2020
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Modified alginates for anti-fibrotic materials and applications
    Patent number: 10426735
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: October 1, 2019
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Compositions Of Crystallized Hydrophobic Compounds And Methods Of Making And Using Same
    Publication number: 20190210976
    Abstract: The present invention provides, in certain embodiments, compositions comprising a uniform population of free, single crystals of a hydrophobic compound. Methods of administering, and processes for preparing, compositions comprising a uniform population of free, single crystals of a hydrophobic compound are also provided.
    Type: Application
    Filed: April 4, 2017
    Publication date: July 11, 2019
    Inventors: Shady Farah, Joshua C. Doloff, Robert S. Langer, Daniel G. Anderson
  • MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS
    Publication number: 20190184067
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 20, 2019
    Inventors: Arturo Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors
    Publication number: 20190083495
    Abstract: Described herein are methods of preventing or reducing fibrosis comprising administering CSF1R inhibitors, coating formulations comprising CSF1R inhibitors, coatings comprising CSF1R inhibitors for implantable medical devices, CSF1R inhibitor coated implantable medical devices, as well as corresponding embodiments comprising additional agents.
    Type: Application
    Filed: April 4, 2017
    Publication date: March 21, 2019
    Applicant: Massachusetts Institute of Technology
    Inventors: Joshua C. Doloff, Shady Farah, Omid Veiseh, Arturo J. Vegas, Robert S. Langer, Daniel G. Anderson
  • MATERIALS WITH IMPROVED PROPERTIES
    Publication number: 20190046690
    Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
    Type: Application
    Filed: November 2, 2016
    Publication date: February 14, 2019
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Robert S. Langer, Daniel G. Anderson
  • MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS
    Publication number: 20180360765
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 20, 2018
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • MATERIALS WITH IMPROVED PROPERTIES
    Publication number: 20180117216
    Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 3, 2018
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Robert S. Langer, Daniel G. Anderson
  • MATERIALS WITH IMPROVED PROPERTIES
    Publication number: 20170246347
    Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 31, 2017
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Robert S. Langer, Daniel G. Anderson
  • MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS
    Publication number: 20170239397
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS
    Publication number: 20170226232
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: November 2, 2016
    Publication date: August 10, 2017
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS
    Publication number: 20160030360
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: August 3, 2015
    Publication date: February 4, 2016
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson